Effector Therapeutics has rallied marquee investors for a sizable $45 million Series A financing, determined to use discoveries in protein translation to mine for new cancer drugs.
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Alnylam Pharmaceuticals CEO John Maraganore has joined Third Rock in the advisory role of venture partner, reunited in a way with his former Millennium Pharmaceuticals colleagues who launched the venture firm 6 years ago.
A little more than a year ago, the startup crew at Lumena Pharmaceuticals was based in North Carolina and working on a new drug for diabetics. But things have changed. The company moved to San Diego, refocused its lead program on a rare liver disease and today announced that it had rounded up $23 million in Series A cash from a trio of venture groups.
Astellas and a pair of venture companies have joined forces to launch a spinout virtual biotech which will pick up mid-stage research work on an experimental therapy for nocturia.
Public biotech companies around the world stayed on a healthy pace last year, boosting top and bottom-line revenue together and extending a solid improvement in the industry's financial performance into its third year, according to Ernst & Young's annual checkup on the numbers.
Ask any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. The...
With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $30 million in a Series A round of financing from top venture firms.
Closing in on the selection of its lead cancer program, San Francisco-based Cleave Biosciences has welcomed the deep-pocketed player New Enterprise Associates to its list of venture backers and topped up its Series A with a $10 million investment in its early-stage drug research work.
Third Rock Ventures has established its third biotech fund in 6 years, bringing in a haul of $516 million for one of the most active groups of early-stage biotech investors in the world. The new fund, which brings the total it's raised to a whopping $1.3 billion-plus, will be used to launch another 16 or so drug developers.